CareFusion Acquires Technology to Automate the Segregation of Pharmaceutical Waste

CareFusion, a medical technology company, has announced it has acquired Vestara, a California-based company focused on developing solutions for the management of pharmaceutical waste.

Advertisement

 

The company said the acquisition will give CareFusion technology to sort and manage dangerous pharmaceutical waste through the expansion of its Pyxis medication management portfolio, according to a news release. Through the acquisition, CareFusion adds the Pyxis EcoStation — a hardware and software system that can help hospitals identify, classify and segregate pharmaceutical waste, while providing records to facilitate tracking and regulatory controls.

 

CareFusion said this will help hospitals reduce cost, improve regulatory controls and facilitate environmental responsibility.

 

“Pharmaceutical waste management is a challenging issue, with many of the nation’s hospitals remaining non-compliant due to complex handling requirements specific to each medication classification and varying regulations at federal, state and local levels,” said Tom Leonard, president of Dispensing Technologies at CareFusion, in the release. “CareFusion can now help in a way that protects their employees, the environment and their bottom line.”

 

Read the news release about the acquisition of Vestara by CareFusion.

Read more from CareFusion:

 

Anesthesiologist on the Move: Dr. Carlos Nunez Joins CareFusion as CMO

 

CareFusion Sells International Surgical Products to Medline for $130M

 

CareFusion Launches Adapter Enabling Uninterrupted Airway Access

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.